Rezolute (RZLT) Expected to Announce Quarterly Earnings on Wednesday

Rezolute (NASDAQ:RZLT) will likely be posting its Q4 2026 results after the market closes on Wednesday, September 16th. Analysts expect Rezolute to announce earnings of ($0.1479) per share for the quarter. Parties may visit the the company’s upcoming Q4 2026 earning results page for the latest details on the call scheduled for Friday, September 25, 2026 at 4:00 PM ET.

Rezolute Stock Up 0.7%

Rezolute stock opened at $4.25 on Tuesday. The business has a 50-day simple moving average of $4.73 and a two-hundred day simple moving average of $3.98. The company has a market cap of $409.24 million, a P/E ratio of -5.18 and a beta of 0.60. Rezolute has a 52-week low of $1.07 and a 52-week high of $11.46.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RZLT. Citizens Jmp raised shares of Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 price objective on the stock in a report on Wednesday, June 3rd. Zacks Research raised shares of Rezolute from a “strong sell” rating to a “hold” rating in a report on Friday, August 14th. Wall Street Zen downgraded shares of Rezolute from a “hold” rating to a “sell” rating in a research report on Tuesday, June 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rezolute in a research note on Friday, July 17th. Finally, BTIG Research lifted their price target on shares of Rezolute from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd. Eight analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.38.

Rezolute Company Profile

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia.